Table 2.
Effect of 1–25 mg/kg/day of N-MCT when administered beginning 2–3 days post HSV-2 inoculation of newborn guinea pigs
| # With Symptomsa (% With symptoms) |
||||||
|---|---|---|---|---|---|---|
| Group | N | Survival (% survival) | # Without Symptoms d (% Without symptoms) | SEM | Respiratory | General Symptoms |
| Control | 11 | 3/11 (27.3%) | 0/11 (0%) | 11/11 (100%) | 11/11 (100%) | 6/11 (54.5%) |
| N-MCT 1 mg/kg @ 2 dpi × 10 days | 9 | 8/9 (88.9%)b | 1/9 (11.1%) | 7/9 (77.8%) | 5/9 (55.6%) | 1/9 (11.1%) |
| N-MCT 5 mg/kg @ 2 dpi × 10 days | 11 | 11/11 (80.0% c | 5/11 (45.5%)d | 4/11 (36.4%) b | 2/11 (18.2%)c | 0/11 (0%)b |
| N-MCT 5 mg/kg @ 3 dpi × 10 days | 10 | 8/10 (80.0%)d | 0/10 (0%) | 8/10 (80%) | 9/10 (90%) | 3/10 (30%) |
| N-MCT 25 mg/kg @ 3 dpi × 10 days | 6 | 6/6 (100%)b | 2/6 (33.3%) | 4/6 (66.7%) | 3/6 (50%) | 0/6 (0%) |
dpi: Day post inoculation
a
As described in methods this includes: Vesicular Lesions, respiratory, eye disease and general symptoms
b
p≤0.01 vs. Control
c
p<0.001 vs. Control
d
p<0.05 vs. Control